About Oncimmune
Oncimmune is a company based in Nottingham (United Kingdom) founded in 2006 by Geoffrey Hamilton Fairley was acquired by Freenome in May 2023. It operates as a Professional Services, and Data-as-a-Service. Oncimmune has completed 1 acquisition, including Protagen. Oncimmune offers products and services including ImmunoINSIGHTS™, Targeted Panels & Arrays, and Bioinformatics & Data Science. Oncimmune operates in a competitive market with competitors including Biodesix, OncoCyte, Broncus, Riverain Tech and ONCOHOST, among others.
- Headquarter Nottingham, United Kingdom
- Founders Geoffrey Hamilton Fairley
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alden Scientific Holdings Incorporated
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$2.87 M (USD), Post-IPO
Oct 21, 2024
-
Investors
Freenome Health
& 4 more
-
Employee Count
Employee Count
- Investments & Acquisitions
-
Acquired by
Freenome
(May 22, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oncimmune
Oncimmune offers a comprehensive portfolio of products and services, including ImmunoINSIGHTS™, Targeted Panels & Arrays, and Bioinformatics & Data Science. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform used for antibody biomarker discovery and analysis.
Services offered for customized biomarker panel development.
Analytics provided for biomarker data integration and insights.
Funding Insights of Oncimmune
- Total Funding Total Funding
- Total Rounds 17
- Last Round Post-IPO — $2.9M
-
First Round
First Round
(01 May 2011)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Post-IPO - Oncimmune | Valuation |
investors |
|
| Dec, 2022 | Amount | Post-IPO - Oncimmune | Valuation |
investors |
|
| Mar, 2021 | Amount | Post-IPO - Oncimmune | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Oncimmune
Oncimmune has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Freenome Health, HHS and UK Research and Innovation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Alternative financing is provided by IPF Partners for healthcare.
|
Founded Year | Domain | Location | |
|
Research and innovation funding is managed for UK advancement.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Oncimmune
Oncimmune has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Protagen. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Autoantibody biomarkers are utilized for autoimmune disease diagnostics.
|
1997 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Oncimmune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oncimmune Comparisons
Competitors of Oncimmune
Oncimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biodesix, OncoCyte, Broncus, Riverain Tech and ONCOHOST, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cancer detection diagnostics assays are developed and offered.
|
|
| domain | founded_year | HQ Location |
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Minimally invasive technologies for lung disease treatment are developed.
|
|
| domain | founded_year | HQ Location |
Software tools are developed for early lung disease detection.
|
|
| domain | founded_year | HQ Location |
AI-based proteomic analysis for oncology therapy planning is offered.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oncimmune
Frequently Asked Questions about Oncimmune
When was Oncimmune founded?
Oncimmune was founded in 2006 and raised its 1st funding round 5 years after it was founded.
Where is Oncimmune located?
Oncimmune is headquartered in Nottingham, United Kingdom.
Who is the current CEO of Oncimmune?
Geoffrey Hamilton Fairley is the current CEO of Oncimmune. They have also founded this company.
What does Oncimmune do?
Oncimmune is engaged in the development of advanced antibody biomarker discovery platforms, primarily through its proprietary ImmunoINSIGHTS engine. The company operates in the healthcare and biotechnology sectors, offering solutions for precision medicine across areas such as immuno-oncology, autoimmune diseases, and infectious diseases. Services include targeted panels, arrays, and bioinformatics for data integration. With a vast antigen library and cutting-edge technology, Oncimmune collaborates with clients to provide insights into the immune system for improved diagnostics and treatments.
Who are the top competitors of Oncimmune?
What products or services does Oncimmune offer?
Oncimmune offers ImmunoINSIGHTS™, Targeted Panels & Arrays, and Bioinformatics & Data Science.
How many acquisitions has Oncimmune made?
Oncimmune has made 1 acquisition, including Protagen.
Who are Oncimmune's investors?
Oncimmune has 5 investors. Key investors include Freenome Health, HHS, UK Research and Innovation, IPF Partners, and Genostics.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.